3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
AbstractAntidepressants are psychiatric agents used for the treatment of different types of depression being at present amongst the most commonly prescribed drug, while their effectiveness and adverse effects are the subject of many studies and competing claims. Having studied five QSAR models predicting the biological activities of 18 antidepressants, already approved for clinical treatment, in interaction with the serotonin transporter (SERT), we attempted to establish the membrane ions’ contributions (sodium, potassium, chlorine and calcium) supplied by donor/acceptor hydrogen bond character and electrostatic field to the antidepressant activity. Significant cross-validated correlation q2 (0.5–0.6) and the fitted correlation r2 (0.7–0.82) coefficients were obtained indicating that the models can predict the antidepressant activity of compounds. Moreover, considering the contribution of membrane ions (sodium, potassium and calcium) and hydrogen bond donor character, we have proposed a library of 24 new escitalopram structures, some of them probably with significantly improved antidepressant activity in comparison with the parent compound.
Share & Cite This Article
AVRAM, S.; BUIU, C.; DUDA-SEIMAN, D.M.; DUDA-SEIMAN, C.; MIHAILESCU, D. 3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders. Sci. Pharm. 2010, 78, 233-248.
AVRAM S, BUIU C, DUDA-SEIMAN DM, DUDA-SEIMAN C, MIHAILESCU D. 3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders. Scientia Pharmaceutica. 2010; 78(2):233-248.Chicago/Turabian Style
AVRAM, Speranta; BUIU, Catalin; DUDA-SEIMAN, Daniel M.; DUDA-SEIMAN, Corina; MIHAILESCU, Dan. 2010. "3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders." Sci. Pharm. 78, no. 2: 233-248.